Genentech, Inc. v. Regeneron Pharmaceuticals, Inc. et al > Summary
Court Case Number 7:11-cv-09463
Filing Date Dec 23, 2011
Court New York Southern District Court
Status Unknown
Plaintiff
Plaintiff Attorneys
6Genentech, Inc
Attorney Name: Scott B. Familant
Baker Botts LLP
Genentech, Inc
Attorney Name: Kenneth A. Gallo
Paul Weiss Rifkind Wharton & Garrison
Genentech, Inc
Attorney Name: Jennifer Gordon
Baker Botts LLP
Genentech, Inc
Attorney Name: John E. Nathan
Paul Weiss Rifkind Wharton & Garrison
Genentech, Inc
Attorney Name: Eric Alan Stone
Paul Weiss Rifkind Wharton & Garrison
Defendant Attorneys
29Regeneron Pharmaceuticals
Attorney Name: Will Charles Autz
Venable
Sanofi
Attorney Name: Will Charles Autz
Venable
Sanofi
Attorney Name: Will Charles Autz
Venable
Sanofi
Attorney Name: Will Charles Autz
Venable
Sanofi Aventis Amerique Du Nord SNC
Attorney Name: Will Charles Autz
Venable
Regeneron Pharmaceuticals
Attorney Name: Morgan Chu
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Dana Lau
Venable
Sanofi
Attorney Name: Dana Lau
Venable
Sanofi
Attorney Name: Dana Lau
Venable
Sanofi
Attorney Name: Dana Lau
Venable
Sanofi Aventis Amerique Du Nord SNC
Attorney Name: Dana Lau
Venable
Regeneron Pharmaceuticals
Attorney Name: Amir A. Naini
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Keith A. Orso
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Scott K. Reed
Venable
Sanofi
Attorney Name: Scott K. Reed
Venable
Sanofi
Attorney Name: Scott K. Reed
Venable
Sanofi
Attorney Name: Scott K. Reed
Venable
Sanofi Aventis Amerique Du Nord SNC
Attorney Name: Scott K. Reed
Venable
Regeneron Pharmaceuticals
Attorney Name: Robert S. Schwartz
Venable
Sanofi
Attorney Name: Robert S. Schwartz
Venable
Sanofi
Attorney Name: Robert S. Schwartz
Venable
Sanofi
Attorney Name: Robert S. Schwartz
Venable
Sanofi Aventis Amerique Du Nord SNC
Attorney Name: Robert S. Schwartz
Venable
Regeneron Pharmaceuticals
Attorney Name: Jason G. Sheasby
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Brian V. Slater
Venable
Sanofi
Attorney Name: Brian V. Slater
Venable
Sanofi
Attorney Name: Brian V. Slater
Venable
Sanofi
Attorney Name: Brian V. Slater
Venable
Sanofi Aventis Amerique Du Nord SNC
Attorney Name: Brian V. Slater
Venable
Counter Defendant
6Genentech, Inc
Attorney Name: Scott B. Familant
Baker Botts LLP
Genentech, Inc
Attorney Name: Kenneth A. Gallo
Paul Weiss Rifkind Wharton & Garrison
Genentech, Inc
Attorney Name: Jennifer Gordon
Baker Botts LLP
Genentech, Inc
Attorney Name: John E. Nathan
Paul Weiss Rifkind Wharton & Garrison
Genentech, Inc
Attorney Name: Eric Alan Stone
Paul Weiss Rifkind Wharton & Garrison
Counter Claimant
18Regeneron Pharmaceuticals
Attorney Name: Will Charles Autz
Venable
Sanofi
Attorney Name: Will Charles Autz
Venable
Sanofi
Attorney Name: Will Charles Autz
Venable
Regeneron Pharmaceuticals
Attorney Name: Morgan Chu
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Dana Lau
Venable
Sanofi
Attorney Name: Dana Lau
Venable
Sanofi
Attorney Name: Dana Lau
Venable
Regeneron Pharmaceuticals
Attorney Name: Amir A. Naini
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Scott K. Reed
Venable
Sanofi
Attorney Name: Scott K. Reed
Venable
Sanofi
Attorney Name: Scott K. Reed
Venable
Regeneron Pharmaceuticals
Attorney Name: Robert S. Schwartz
Venable
Sanofi
Attorney Name: Robert S. Schwartz
Venable
Sanofi
Attorney Name: Robert S. Schwartz
Venable
Regeneron Pharmaceuticals
Attorney Name: Jason G. Sheasby
Irell & Manella LLP
Regeneron Pharmaceuticals
Attorney Name: Brian V. Slater
Venable
Sanofi
Attorney Name: Brian V. Slater
Venable
Sanofi
Attorney Name: Brian V. Slater
Venable
Cause
35:271 Patent Infringement
Related Patents
| Doc No | Title | Issue date |
|---|---|---|
| 06897294 | Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production | May 24, 2005 |
| 06383486 | Inhibitors of vascular endothelial growth factor activity, their uses and processes for their production | May 7, 2002 |
| 06100071 | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production | Aug 8, 2000 |
